ACVR1 (Activin A Receptor Type 1)

In recent years, oral therapy with the JAK1/2 inhibitor ruxolitinib has become the standard of care. Since 2021, the JAK2/FLT3 inhibitor fedratinib has also been approved in the EU (note: in Switzerland, fedratinib will no longer be available as of February 28, 2025, as Swissmedic did not extend its time-limited approval)...Compared to the other two JAK inhibitors, momelotinib is particularly effective in patients with clinically symptomatic moderate to severe anemia. Results from studies investigating additional JAK inhibitors, combination therapies, and novel agents have also demonstrated significant efficacy and point toward future therapeutic developments, although these approaches are not yet available for routine clinical practice.

Achieving meaningful survival benefit for patients with DMG requires a multidisciplinary approach bridging neuro-oncology, advanced imaging, and nanomaterials development. Future research must prioritize four key areas: (1) optimizing NP properties for superior brainstem penetration, (2) leveraging DMG-specific markers for active delivery, (3) integrating theranostics for real-time monitoring, and (4) developing scalable, clinically compliant manufacturing.

Collectively, our findings suggest that SPLC might be activated in human tumor cells, serving as a potential pathway for gaining tumor-initiating ability that involves human PGC-related pathways. These results demonstrate that the acquisition of PGC-like fate in somatic cells drives tumor malignant progression, providing a potential paradigm for targeted cancer therapy.

In the TQT study, 42 subjects received single doses of pacritinib 400 mg, moxifloxacin 400 mg (positive control), and placebo in a crossover design. Median QTcF changes from pre-dose to 4 h post-dose were minimal (+2.7 and -0.3 ms, respectively), and no dose-response relationship was identified. These findings suggest that pacritinib exposure is unlikely to be correlated with QT prolongation.

Momelotinib demonstrated meaningful clinical benefit and acceptable safety in cytopenic patients pretreated with ruxolitinib, which supports its role after ruxolitinib failure.

Subsequent optimization of this compound resulted in M4K3250 (20), a compound with improved ALK2 degradation potency. The compounds described have utility for studying the role of ALK2 in human disease and possess translational potential in drug discovery.

This single-center cohort from Türkiye confirms the key clinical features of FOP associated with both common and rare ACVR1 variants and expands the radiological findings with notable features such as pontine malformation. It also highlights scalp nodules as a potential early diagnostic clue, emphasizing the importance of early clinical recognition and timely molecular confirmation, while providing insights that may inform future therapeutic approaches.

P2, N=113, Terminated, Clementia Pharmaceuticals Inc. | Trial completion date: Mar 2029 --> Mar 2026 | Completed --> Terminated | Trial primary completion date: Mar 2029 --> Mar 2026; Following the planned FALKON Part A primary analysis, the study did not meet its primary endpoint of reducing heterotopic ossification (HO) volume compared with placebo and met predefined futility criteria.

In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.

Early-stage FOP exhibits distinct histological features, with congenital hallux deformity serving as a crucial diagnostic clue. Molecular testing for ACVR1 mutations facilitates early disease diagnosis.

While no JAK inhibitor has demonstrated clear disease-modifying effects in MF, pacritinib's non-myelosuppressive profile, unique activity against IRAK1, and potential anemia benefit via ACVR1 inhibition suggests potential utility as a backbone for future combination strategies. Ongoing and future studies will be critical to further define its role in phenotype-driven MF management.

P2, N=113, Completed, Clementia Pharmaceuticals Inc. | Recruiting --> Completed